Also found in: Acronyms, Wikipedia.
Pharmacologic class: Mitosis inhibitor
Therapeutic class: Antineoplastic
Pregnancy risk category D
FDA Box Warning
• Give under supervision of physician experienced in cancer chemotherapy, in facility with adequate diagnostic and treatment resources.
• Treatment-related death is more likely if patient has abnormal hepatic function, is receiving higher doses, or has non-small-cell lung cancer and history of platinum-based chemotherapy and is receiving drug as a single agent at dosage of 100 mg/m2.
• Generally, drug shouldn't be given to patients with bilirubin level above upper limit of normal (ULN) or those with aspartate aminotransferase (AST) or alanine aminotransferase (ALT) above 1.5 × ULN concomitant with alkaline phosphatase (ALP) level above 2.5 × ULN. Bilirubin elevations or transaminase abnormalities concurrent with ALP abnormalities increases patient's risk for grade 4 neutropenia, febrile neutropenia, infections, severe thrombocytopenia, severe stomatitis, severe skin toxicity, and toxic death. Patients with isolated transaminase elevations above 1.5 × ULN have higher rate of grade 4 febrile neutropenia, but without increased incidence of toxic death. Before each cycle, obtain bilirubin, ALT or AST, and ALP values and have physician review them.
• Don't give to patients with neutrophil count below 1,500 cells/mm3. Obtain frequent blood cell counts to monitor for neutropenia (which may be severe and cause infection).
• Severe hypersensitivity reactions and fatal anaphylaxis (rare) have occurred in patients who received recommended 3-day dexamethasone premedication. If hypersensitivity reaction occurs, discontinue docetaxel immediately and give appropriate therapy. Don't give drug to patients with history of severe hypersensitivity reactions to it or other drugs containing polysorbate 80. Severe fluid retention may occur despite dexamethasone premedication regimen.
Inhibits cellular mitosis by disrupting microtubular network
Injection concentrate: 20 mg, 80 mg
⊘Indications and dosages
➣ Locally advanced or metastatic breast cancer unresponsive to previous regimens
Adults: 60 to 100 mg/m2 I.V. over 1 hour q 3 weeks as single agent
➣ Adjuvant treatment of operable node-positive breast cancer
Adults: 75 mg/m2 1 hour after doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 q 3 weeks for six courses
➣ Locally advanced or metastatic non-small-cell lung cancer (NSCLC) after platinum therapy failure
Adults: 75 mg/m2 I.V. over 1 hour q 3 weeks as single agent
➣ Unresectable locally advanced or metastatic NSCLC in chemotherapynaïve patients
Adults: 75 mg/m2 I.V. over 1 hour q 3 weeks followed by cisplatin as ordered
➣ Androgen-independent (hormone refractory) metastatic prostate cancer
Adults: 75 mg/m2 I.V. over 1 hour q 3 weeks with 5 mg prednisone P.O. b.i.d. continuously
➣ Gastric adenocarcinoma cancer
Adults: 75 mg/m2 as a 1-hour infusion, followed by cisplatin as a 1- to 3-hour infusion (both on day 1 only), followed by fluorouracil given as a 24-hour continuous I.V. infusion for 5 days, starting at the end of the cisplatin infusion. Treatment is repeated q 3 weeks.
➣ Squamous cell carcinoma of head and neck
Adults:Induction chemotherapy followed by radiotherapy-75 mg/m2 I.V. as 1-hour infusion followed by cisplatin 75 mg/m2 I.V. over 1 hour (both on day 1 only), followed by fluorouracil 750 mg/m2 given as 24-hour continuous I.V. infusion daily for 5 days, starting at end of cisplatin infusion. Treatment is repeated q 3 weeks for four cycles.
Adults:Induction chemotherapy followed by chemoradiotherapy-75 mg/m2 I.V. as 1-hour infusion on day 1, followed by cisplatin 100 mg/m2 I.V. as 30-minute to 3-hour infusion, followed by fluorouracil 1,000 mg/m2/day I.V. as continuous infusion from day 1 to day 4. Treatment is repeated q 3 weeks for three cycles.
• Febrile neutropenia
• Hypersensitivity to drug or polysorbate 80
• Hepatic impairment
• Neutrophil count below 1,500 cells/mm3
Use cautiously in:
• females of childbearing age
• pregnant or breastfeeding patients.
• Assess bilirubin, ALT, AST, and ALP levels before starting each cycle of drug therapy.
• Premedicate patient with oral corticosteroids before docetaxel administration to reduce fluid retention and severity of hypersensitivity reactions.
• Premedicate patient with antiemetics and hydrate with I.V. fluids, as prescribed, before cisplatin administration.
☞ Don't let drug concentrate contact plasticized polyvinyl chloride equipment or devices.
• Know that when used for prostate cancer, drug must be given with prednisone, as prescribed.
• Dilute with accompanying diluent solution; rotate vial gently to mix. Once foam has largely dissipated, withdraw prescribed amount of drug and mix in glass or polypropylene bottle or in plastic bag with 250 ml of normal saline solution or dextrose 5% in water.
• Mix solution thoroughly and infuse over 1 hour, using polyethylene-lined infusion set.
CNS: fatigue, asthenia, neurosensory deficits, peripheral neuropathy
CV: peripheral edema, cardiac tamponade, pericardial effusion
GI: nausea, vomiting, diarrhea, stomatitis, ascites
Hematologic: anemia, thrombocytopenia, leukopenia
Musculoskeletal: myalgia, joint pain
Respiratory: bronchospasm, pulmonary edema
Skin: alopecia, rash, dermatitis, desquamation, erythema, nail disorders
Other: edema, hypersensitivity reactions including anaphylaxis
Drug-drug.Antineoplastics: additive bone marrow depression
Cyclosporine, erythromycin, ketoconazole, troleandomycin: significant change in docetaxel effects
Live-virus vaccines: increased risk of infection
☞ Watch for signs and symptoms of anaphylaxis or other hypersensitivity reactions, especially with first two doses.
• Monitor vital signs and fluid intake and output. Watch for signs and symptoms of fluid overload and bronchospasm.
• Monitor CBC, and assess for signs and symptoms of blood dyscrasias.
• Closely monitor neutrophil and platelet counts before and during therapy.
• Observe I.V. site frequently for extravasation.
• Assess neurologic status to detect neurosensory deficits and peripheral neuropathy.
• Instruct patient to weigh himself daily and to immediately report sudden weight gain or difficulty breathing.
☞ Tell patient to report signs and symptoms of blood dyscrasias. Inform him that he'll undergo frequent blood testing to monitor these effects.
☞ Advise patient to immediately report rash or difficulty breathing.
• Inform patient that nail disorders and hair loss are common with docetaxel use, but that hair and nails will grow back after therapy ends.
• Advise female patient of childbearing age to use effective contraception during therapy and to notify prescriber if she suspects pregnancy.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs mentioned above.